All In Biotech

Drug Trial Radar · NCT06829173

Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas

A Phase 0/I Study to Assess the Safety and Tolerability of XRD-0394 in Combination With Radiation Therapy in Patients With High Grade Gliomas

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

May 2027

Study completion May 2031

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gliomas.

Conditions

  • High-Grade Glioma

Interventions

  • XRD-0394Drug

    Administered orally; small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and DNA-PK.

  • Radiation TherapyRadiation

    For Cohort A and Cohort B, the neoadjuvant "boost" radiation dose is 1400cGy delivered over 7 fractions, and the adjuvant radiation dose is 5000cGy delivered over 25 fractions for a total dose of 6400cGy over 32 fractions, accounting for the treatment break between boost and adjuvant RT. For Cohort C, the radiation dose is 3500cGy delivered over 10 fractions.

  • Surgical ResectionProcedure

    Resection of tumor tissue.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who Experience Dose-Limiting Toxicities (DLTs)Time frame: End of DLT Monitoring Period (Pre-surgical dose-escalation: Day 8; Cohort C: Day 44; Cohorts A & B: Day 108)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.